These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24691786)

  • 1. Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting risks earlier.
    Alves C; Marques FB; Macedo AF
    Eur J Clin Pharmacol; 2014 Jun; 70(6):745-56. PubMed ID: 24691786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sources of information used by regulatory agencies on the generation of drug safety alerts.
    Alves C; Macedo AF; Marques FB
    Eur J Clin Pharmacol; 2013 Dec; 69(12):2083-94. PubMed ID: 23893047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016.
    Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1054-1063. PubMed ID: 32696556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced ocular adverse reactions: review of the safety alerts issued during the last decade.
    Penedones A; Mendes D; Alves C; Marques FB
    J Ocul Pharmacol Ther; 2015 Jun; 31(5):258-68. PubMed ID: 25871404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of drug safety alerts issued by the Spanish Medicines Agency.
    Montané E; Santesmases J
    Front Pharmacol; 2023; 14():1090707. PubMed ID: 36794271
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulatory alerts for dietary supplements in Canada and the United States, 2005-13.
    Abe AM; Hein DJ; Gregory PJ
    Am J Health Syst Pharm; 2015 Jun; 72(11):966-71. PubMed ID: 25987692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Earlier identification of risks: cumulative probability analysis of time to safety alerts for therapeutic monoclonal antibodies.
    Stanulović V; Kadlecová P; Zelkó R; Kerpel-Fronius S
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):499-503. PubMed ID: 25997549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thirteen years of medication alerts issued by the Brazilian Health Regulatory Agency (ANVISA): What is the profile?
    Ferreira VC; Ferreira GC; Baldoni AO
    J Eval Clin Pract; 2020 Jun; 26(3):957-961. PubMed ID: 31290584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA drug safety communications: a narrative review and clinical considerations for older adults.
    Marcum ZA; Vande Griend JP; Linnebur SA
    Am J Geriatr Pharmacother; 2012 Aug; 10(4):264-71. PubMed ID: 22683398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perils and pitfalls of long-term effects of proton pump inhibitors.
    Wilhelm SM; Rjater RG; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):443-51. PubMed ID: 23927671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Alerts: An Observational Study in Portugal.
    Soares S; Roque F; Teixeira Rodrigues A; Figueiras A; Herdeiro MT
    Clin Ther; 2015 Sep; 37(9):2122-8. PubMed ID: 26256430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Existence of Notoriety Bias in FDA Adverse Event Reporting System Database and Its Impact on Signal Strength.
    Neha R; Subeesh V; Beulah E; Gouri N; Maheswari E
    Hosp Pharm; 2021 Jun; 56(3):152-158. PubMed ID: 34024922
    [No Abstract]   [Full Text] [Related]  

  • 16. Actions of the National Regulatory Authorities in 10 Low- and Middle-Income Countries Following Stringent Regulatory Authority Safety Alerts on Rosiglitazone.
    Nwokike J; Kabore L; Stergachis A
    Ther Innov Regul Sci; 2015 Mar; 49(2):279-283. PubMed ID: 30222412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
    Mendes D; Alves C; Batel Marques F
    Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-approval safety issues with innovative drugs: a European cohort study.
    Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
    Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.